Edwards Lifesciences Corporation (EW)
USD 75.65
(0.63%)
USD 75.65
(0.63%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 670 Million USD | 0.63% |
| 2022 | 665.8 Million USD | 0.15% |
| 2021 | 664.8 Million USD | -0.43% |
| 2020 | 667.7 Million USD | 2.2% |
| 2019 | 653.3 Million USD | 10.02% |
| 2018 | 593.8 Million USD | 35.45% |
| 2017 | 438.4 Million USD | -46.69% |
| 2016 | 822.3 Million USD | 37.07% |
| 2015 | 599.9 Million USD | 0.3% |
| 2014 | 598.1 Million USD | 0.84% |
| 2013 | 593.1 Million USD | 213.31% |
| 2012 | 189.3 Million USD | 25.86% |
| 2011 | 150.4 Million USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 90.3 Million USD | -48.55% |
| 2008 | 175.5 Million USD | 184.44% |
| 2007 | 61.7 Million USD | -73.84% |
| 2006 | 235.9 Million USD | -25.37% |
| 2005 | 316.1 Million USD | 18.35% |
| 2004 | 267.1 Million USD | 4.42% |
| 2003 | 255.8 Million USD | 4.2% |
| 2002 | 245.5 Million USD | -20.81% |
| 2001 | 310 Million USD | -15.53% |
| 2000 | 367 Million USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 597.3 Million USD | 0.02% |
| 2024 Q1 | 597.2 Million USD | 0.03% |
| 2023 Q4 | 670 Million USD | 0.48% |
| 2023 Q1 | 662.7 Million USD | -0.47% |
| 2023 Q2 | 660.2 Million USD | -0.38% |
| 2023 Q3 | 666.8 Million USD | 1.0% |
| 2023 FY | 670 Million USD | 0.63% |
| 2022 Q4 | 665.8 Million USD | 0.38% |
| 2022 Q3 | 663.3 Million USD | 0.58% |
| 2022 Q1 | 664.3 Million USD | -0.08% |
| 2022 Q2 | 659.5 Million USD | -0.72% |
| 2022 FY | 665.8 Million USD | 0.15% |
| 2021 Q2 | 659.1 Million USD | -0.48% |
| 2021 Q4 | 664.8 Million USD | 0.74% |
| 2021 FY | 664.8 Million USD | -0.43% |
| 2021 Q1 | 662.3 Million USD | -0.81% |
| 2021 Q3 | 659.9 Million USD | 0.12% |
| 2020 Q1 | 650.3 Million USD | -0.46% |
| 2020 Q2 | 660.7 Million USD | 1.6% |
| 2020 FY | 667.7 Million USD | 2.2% |
| 2020 Q4 | 667.7 Million USD | 0.27% |
| 2020 Q3 | 665.9 Million USD | 0.79% |
| 2019 Q1 | 643.6 Million USD | 8.39% |
| 2019 Q3 | 646.6 Million USD | 0.33% |
| 2019 FY | 653.3 Million USD | 10.02% |
| 2019 Q4 | 653.3 Million USD | 1.04% |
| 2019 Q2 | 644.5 Million USD | 0.14% |
| 2018 Q1 | 456 Million USD | 4.01% |
| 2018 FY | 593.8 Million USD | 35.45% |
| 2018 Q4 | 593.8 Million USD | 0.03% |
| 2018 Q2 | 593.9 Million USD | 30.24% |
| 2018 Q3 | 593.6 Million USD | -0.05% |
| 2017 Q2 | 1.01 Billion USD | 19.92% |
| 2017 FY | 438.4 Million USD | -46.69% |
| 2017 Q4 | 438.4 Million USD | -57.6% |
| 2017 Q3 | 1.03 Billion USD | 1.69% |
| 2017 Q1 | 847.9 Million USD | 3.11% |
| 2016 Q3 | 600.6 Million USD | -0.32% |
| 2016 Q1 | 602.2 Million USD | 0.38% |
| 2016 Q4 | 822.3 Million USD | 36.91% |
| 2016 FY | 822.3 Million USD | 37.07% |
| 2016 Q2 | 602.5 Million USD | 0.05% |
| 2015 Q3 | 604.9 Million USD | 0.77% |
| 2015 Q1 | 602.7 Million USD | 0.77% |
| 2015 FY | 599.9 Million USD | 0.3% |
| 2015 Q2 | 600.3 Million USD | -0.4% |
| 2015 Q4 | 599.9 Million USD | -0.83% |
| 2014 Q3 | 596.4 Million USD | -0.27% |
| 2014 Q1 | 725.4 Million USD | 22.31% |
| 2014 Q2 | 598 Million USD | -17.56% |
| 2014 FY | 598.1 Million USD | 0.84% |
| 2014 Q4 | 598.1 Million USD | 0.29% |
| 2013 Q2 | 227.3 Million USD | 17.96% |
| 2013 Q3 | 532.1 Million USD | 134.1% |
| 2013 Q4 | 593.1 Million USD | 11.46% |
| 2013 FY | 593.1 Million USD | 213.31% |
| 2013 Q1 | 192.7 Million USD | 1.8% |
| 2012 Q4 | 189.3 Million USD | 7.92% |
| 2012 FY | 189.3 Million USD | 25.86% |
| 2012 Q3 | 175.4 Million USD | -5.24% |
| 2012 Q2 | 185.1 Million USD | 3.18% |
| 2012 Q1 | 179.4 Million USD | 19.28% |
| 2011 FY | 150.4 Million USD | 0.0% |
| 2011 Q4 | 150.4 Million USD | -14.06% |
| 2011 Q3 | 175 Million USD | 0.11% |
| 2011 Q2 | 174.8 Million USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q2 | 177.5 Million USD | 37.28% |
| 2010 Q4 | - USD | -100.0% |
| 2010 Q3 | 100.6 Million USD | -43.32% |
| 2010 Q1 | 129.3 Million USD | 43.19% |
| 2009 Q4 | 90.3 Million USD | -11.73% |
| 2009 Q3 | 102.3 Million USD | -10.18% |
| 2009 Q1 | 123 Million USD | -29.91% |
| 2009 Q2 | 113.9 Million USD | -7.4% |
| 2009 FY | 90.3 Million USD | -48.55% |
| 2008 FY | 175.5 Million USD | 184.44% |
| 2008 Q1 | 62.9 Million USD | 1.94% |
| 2008 Q2 | 141.7 Million USD | 125.28% |
| 2008 Q3 | 202.8 Million USD | 43.12% |
| 2008 Q4 | 175.5 Million USD | -13.46% |
| 2007 Q4 | 61.7 Million USD | 0.82% |
| 2007 Q1 | 224.5 Million USD | -4.83% |
| 2007 Q2 | 57.6 Million USD | -74.34% |
| 2007 Q3 | 61.2 Million USD | 6.25% |
| 2007 FY | 61.7 Million USD | -73.84% |
| 2006 Q3 | 253 Million USD | -9.51% |
| 2006 FY | 235.9 Million USD | -25.37% |
| 2006 Q4 | 235.9 Million USD | -6.76% |
| 2006 Q2 | 279.6 Million USD | -3.25% |
| 2006 Q1 | 289 Million USD | -8.57% |
| 2005 Q2 | 269.6 Million USD | -2.25% |
| 2005 Q4 | 316.1 Million USD | 25.69% |
| 2005 Q3 | 251.5 Million USD | -6.71% |
| 2005 FY | 316.1 Million USD | 18.35% |
| 2005 Q1 | 275.8 Million USD | 3.26% |
| 2004 Q1 | 334.5 Million USD | 30.77% |
| 2004 Q2 | 312.8 Million USD | -6.49% |
| 2004 Q3 | 269.2 Million USD | -13.94% |
| 2004 Q4 | 267.1 Million USD | -0.78% |
| 2004 FY | 267.1 Million USD | 4.42% |
| 2003 Q4 | 255.8 Million USD | -12.73% |
| 2003 Q1 | 276.9 Million USD | 12.79% |
| 2003 Q2 | 307.3 Million USD | 10.98% |
| 2003 FY | 255.8 Million USD | 4.2% |
| 2003 Q3 | 293.1 Million USD | -4.62% |
| 2002 Q3 | 279.9 Million USD | -5.73% |
| 2002 Q4 | 245.5 Million USD | -12.29% |
| 2002 Q2 | 296.9 Million USD | 2.1% |
| 2002 Q1 | 290.8 Million USD | -6.19% |
| 2002 FY | 245.5 Million USD | -20.81% |
| 2001 FY | 310 Million USD | -15.53% |
| 2001 Q1 | 352.9 Million USD | -3.84% |
| 2001 Q4 | 310 Million USD | -8.58% |
| 2001 Q3 | 339.1 Million USD | 0.03% |
| 2001 Q2 | 339 Million USD | -3.94% |
| 2000 FY | 367 Million USD | 0.0% |
| 2000 Q4 | 367 Million USD | 5.4% |
| 2000 Q3 | 348.2 Million USD | 8.47% |
| 2000 Q2 | 321 Million USD | 0.63% |
| 2000 Q1 | 319 Million USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Abbott Laboratories | 13.59 Billion USD | 95.073% |
| Allurion Technologies Inc. | 2.3 Million USD | -28954.64% |
| Artivion, Inc. | 305.53 Million USD | -119.29% |
| Avanos Medical, Inc. | 159.4 Million USD | -320.326% |
| Butterfly Network, Inc. | 22.83 Million USD | -2834.092% |
| Butterfly Network, Inc. | 22.83 Million USD | -2834.092% |
| Bio-Rad Laboratories, Inc. | 1.18 Billion USD | 43.672% |
| Boston Scientific Corporation | 8.96 Billion USD | 92.523% |
| CONMED Corporation | 971.48 Million USD | 31.033% |
| Paragon 28, Inc. | 109.79 Million USD | -510.206% |
| Glaukos Corporation | 383.73 Million USD | -74.598% |
| Globus Medical, Inc. | 417.4 Million USD | -60.517% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | -2596.611% |
| Integer Holdings Corporation | 959.92 Million USD | 30.203% |
| Medtronic plc | 23.87 Billion USD | 97.194% |
| Myomo, Inc. | 115.16 Thousand USD | -581699.236% |
| Nevro Corp. | 211.47 Million USD | -216.828% |
| Owlet, Inc. | 22 Thousand USD | -3045354.545% |
| Penumbra, Inc. | 220.9 Million USD | -203.292% |
| Vicarious Surgical Inc. | 13.78 Million USD | -4760.355% |
| Smith & Nephew plc | 2.17 Billion USD | 69.195% |
| STERIS plc | 3.12 Billion USD | 78.527% |
| Stryker Corporation | 10.9 Billion USD | 93.854% |
| Vapotherm, Inc. | 109.97 Million USD | -509.213% |
| Zimmer Biomet Holdings, Inc. | 4.86 Billion USD | 86.236% |